Himmelfarb J, et al. - This randomized, double-blind, placebo-controlled study was implemented to assess the impacts of THR-184, a bone morphogenetic protein-7 agonist, in patients at high risk for AKI following cardiac surgery. No reduction was evident in the incidence, severity, or duration of AKI after cardiac surgery in high-risk patients as a result of administration of perioperative THR-184 through a range of dose exposures, compared with placebo.